Cell Therapy of Vascular and Neuropathic Complications of Diabetes: Can We Avoid Limb Amputation?

Fecha de publicación: 15/12/2023 Fecha Ahead of Print: 15/12/2023

Autores de IIS La Fe

Manuel Miralles Hernández

Autor

Participantes ajenos a IIS La Fe

Soria B
Escacena N
Gonzaga A
Soria-Juan B
Andreu E
Hmadcha A
Gutierrez-Vilchez AM
Cahuana G
Tejedo JR
De la Cuesta A
García-Gómez S
Hernández-Blasco L

Grupos

Hemostasia, Trombosis, Arteriosclerosis y Biología vascular

Investigador Principal

Pilar Medina Badenes

Abstract

Globally, a leg is amputated approximately every 30 seconds, with an estimated 85 percent of these amputations being attributed to complications arising from diabetic foot ulcers (DFU), as stated by the American Diabetes Association. Peripheral arterial disease (PAD) is a risk factor resulting in DFU and can, either independently or in conjunction with diabetes, lead to recurring, slow-healing ulcers and amputations. According to guidelines amputation is the recommended treatment for patients with no-option critical ischemia of the limb (CTLI). In this article we propose cell therapy as an alternative strategy for those patients. We also suggest the optimal time-frame for an effective therapy, such as implanting autologous mononuclear cells (MNCs), autologous and allogeneic mesenchymal stromal cells (MSC) as these treatments induce neuropathy relief, regeneration of the blood vessels and tissues, with accelerated ulcer healing, with no serious side effects, proving that advanced therapy medicinal product (ATMPs) application is safe and effective and, hence, can significantly prevent limb amputation.

Datos de la publicación

ISSN/ISSNe:: 1661-6596, 1661-6596
Tipo:: Article
Páginas:: -
DOI:: 10.3390/ijms242417512
Factor de Impacto:: 1,176 SCImago ℠
Cuartil:: Q1 SCImago ℠

Documentos

No hay documentos

Métricas

Filiaciones

Soria B:: Institute of Biomedical Research ISABIAL of the University Miguel Hernández, Dr. Balmis General and University Hospital, 03010 Alicante, Spain

Institute of Bioengineering, University Miguel Hernández, 03202 Elche, Spain

CIBERDEM Network Research Center for Diabetes and Associated Metabolic Diseases, Carlos III Health Institute, 28029 Madrid, Spain
Escacena N:: Fresci Consultants, Human Health Innovation, 08025 Barcelona, Spain
Gonzaga A:: Institute of Biomedical Research ISABIAL of the University Miguel Hernández, Dr. Balmis General and University Hospital, 03010 Alicante, Spain

Institute of Bioengineering, University Miguel Hernández, 03202 Elche, Spain
Soria-Juan B:: Reseaux Hôpitalieres Neuchatelois et du Jura, 2000 Neuchâtel, Switzerland
Andreu E:: Institute of Biomedical Research ISABIAL of the University Miguel Hernández, Dr. Balmis General and University Hospital, 03010 Alicante, Spain

Department of Applied Physics, University Miguel Hernández Elche, 03202 Elche, Spain
Hmadcha A:: Biosanitary Research Institute (IIB-VIU), Valencian International University (VIU), 46002 Valencia, Spain

Department of Molecular Biology, University Pablo de Olavide, 41013 Sevilla, Spain
Gutierrez-Vilchez AM:: Institute of Bioengineering, University Miguel Hernández, 03202 Elche, Spain

Department of Pharmacology, Pediatrics and Organic Chemistry, University Miguel Hernández, 03202 Elche, Spain
Cahuana G:: Department of Molecular Biology, University Pablo de Olavide, 41013 Sevilla, Spain
Tejedo JR:: CIBERDEM Network Research Center for Diabetes and Associated Metabolic Diseases, Carlos III Health Institute, 28029 Madrid, Spain

Department of Molecular Biology, University Pablo de Olavide, 41013 Sevilla, Spain
De la Cuesta A:: Hospital Victoria Eugenia, Cruz Roja, 41009 Sevilla, Spain
Miralles M:: University and Polytechnic Hospital La Fe, 46026 Valencia, Spain
García-Gómez S:: Cell Therapy Centre, Nottingham Trent University, Nottingham NG1 4FQ, UK
Hernández-Blasco L:: Institute of Biomedical Research ISABIAL of the University Miguel Hernández, Dr. Balmis General and University Hospital, 03010 Alicante, Spain